The present invention provides a method for inhibiting androgen receptor (AR)-containing tumor cell growth in a subject in need thereof, comprising administrating to said subject a pharmaceutically effective amount of a damaged-DNA binding protein 2 (DDB2) and a pharmaceutically acceptable carrier. The present invention also provides a method for inhibiting androgen receptor (AR)-containing tumor cell growth in a subject in need thereof, comprising administrating to said subject a pharmaceutically effective amount of an expression vector comprising a gene encoding a damaged-DNA binding protein 2 (DDB2) and a pharmaceutically acceptable carrier. In a preferred embodiment, the expression vector is a plasmid vector.